{"name":"China International Neuroscience Institution","slug":"china-international-neuroscience-institution","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Preemptive Analgesia Of Dexmedetomidine","genericName":"Preemptive Analgesia Of Dexmedetomidine","slug":"preemptive-analgesia-of-dexmedetomidine","indication":"Preemptive analgesia to reduce postoperative pain","status":"marketed"},{"name":"Preemptive Dexmedetomidine injection","genericName":"Preemptive Dexmedetomidine injection","slug":"preemptive-dexmedetomidine-injection","indication":"Preoperative sedation and anxiolysis","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Propofol half","genericName":"Propofol half","slug":"propofol-half","indication":"Other","status":"marketed"},{"name":"2% Sevoflurane","genericName":"2% Sevoflurane","slug":"2-sevoflurane","indication":"Other","status":"marketed"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"hydroxyethl starch","genericName":"hydroxyethl starch","slug":"hydroxyethl-starch","indication":"Acute blood loss and hypovolemia requiring volume replacement during surgery or trauma","status":"marketed"}]}],"pipeline":[{"name":"hydroxyethl starch","genericName":"hydroxyethl starch","slug":"hydroxyethl-starch","phase":"marketed","mechanism":"Hydroxyethyl starch (HES) is a synthetic colloid that expands intravascular volume by increasing plasma oncotic pressure and fluid retention in the vascular space.","indications":["Acute blood loss and hypovolemia requiring volume replacement during surgery or trauma"],"catalyst":""},{"name":"Preemptive Analgesia Of Dexmedetomidine","genericName":"Preemptive Analgesia Of Dexmedetomidine","slug":"preemptive-analgesia-of-dexmedetomidine","phase":"marketed","mechanism":"Dexmedetomidine is a selective alpha-2 adrenergic agonist that reduces pain perception and provides analgesia through central nervous system effects.","indications":["Preemptive analgesia to reduce postoperative pain","Perioperative sedation and analgesia"],"catalyst":""},{"name":"Propofol half","genericName":"Propofol half","slug":"propofol-half","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"2% Sevoflurane","genericName":"2% Sevoflurane","slug":"2-sevoflurane","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Preemptive Dexmedetomidine injection","genericName":"Preemptive Dexmedetomidine injection","slug":"preemptive-dexmedetomidine-injection","phase":"marketed","mechanism":"Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.","indications":["Preoperative sedation and anxiolysis","Perioperative analgesia and sedation","Reduction of anesthetic and opioid requirements during surgery"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE05aVdFX3MyY2dwTVNEWnhHR2tpNDRtWXFuZ05CLVNuUEwtV0hheVdFVjFwY2FtbjlpWTJZb0lRWFdMcFZQbGhyUl9VNlBibkdmRkpURmtVMTJrbV9qMUFCS3pzUURZWjVsN2xZa0FpX3FjRkRO?oc=5","date":"2026-03-16","type":"pipeline","source":"Fortune Business Insights","summary":"Neuroscience Market Size, Industry Share, and Forecast, 2034 - Fortune Business Insights","headline":"Neuroscience Market Size, Industry Share, and Forecast, 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQMDNJWGlWdWR6N3M3d1B3bXQ5TWo3dUIzWFFZbDJaWnRRbExvd01JRzdsT1d0Z1V3dTI2UWdsTXhUZTE3a2xlOHRPa0x6aUZaVUhHaTJQaGNKUlpaMFZtS0VpYmtuT3BWMnpfcWZjS1RKTmVTTVdVZWtTTzR3NkdvRFprbjdHRnd1b09JalBnMm1GUm1ncm9uZw?oc=5","date":"2025-09-18","type":"pipeline","source":"www.vic.gov.au","summary":"Health and Life Sciences - www.vic.gov.au","headline":"Health and Life Sciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQeXNsdlF4OGM4NkhUNUFwNVdPQlR3emhMVzJrVk1OVWY5YjVNSUdXZ1RYN0lQSTJ1bWdQaHBIQmVZOXVHX2FPR2lWVzM3dUpiT3ZkeGp6dGhfNEZ2Q25ibUZrQU5DVVRiMWJfcW5sLUJ5VHk4aDRoVGlyd3AxUjQyZm5xa0tqOHpEZkNiV24zbzUtbGc5RnFNSEoxVlZtTzJ1RVB6UVZpcnNOZnJNLXF3LXVlM0hyMlRqRnJwMkhfSFg5bHVDZi00T1BUb0kwMjJ2TkJUTHA2NXc?oc=5","date":"2025-08-11","type":"deal","source":"BioPharma APAC","summary":"AXA Partners with Hainan Boao Lecheng to Pioneer Innovative Cross-Border Medical Insurance Models - BioPharma APAC","headline":"AXA Partners with Hainan Boao Lecheng to Pioneer Innovative Cross-Border Medical Insurance Models","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5wcDVMa0M2cURfLXo3TVB1SFVLc2tBa3VlOTdHdzJvMlc3ZVpQT2tMU242aTFNdDFKSFMzRkJNeUg0UUxmc21aWXBQVmZ5cHhFdWtQdGpPRjVwVGp4Yk5R?oc=5","date":"2025-07-21","type":"pipeline","source":"Nature","summary":"The rise of China’s pharmaceutical industry from 2015–2024: a decade of innovation - Nature","headline":"The rise of China’s pharmaceutical industry from 2015–2024: a decade of innovation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQSnNnb1ltUHc4MDFtdkhCbnRDalpjaVpfajl5TnBsV0FweW5wTWxvWWpYTnh1TDBGam9OM2t3cTR5QW9TNUE4V3NuTTJIZENlRGdQUjJWeWJmZlRIbkpIX0ZCb2pGUF9aenF6OHBjeDNGMjBNZWVRUTRDczliZHpKV2VOVEt6MHI0cUtYV1ZvaEdQbk04TDBPLTd0dmU0OEotMjdROA?oc=5","date":"2025-07-09","type":"deal","source":"Fierce Biotech","summary":"Novartis inks $175M option deal for Sironax’s blood-brain barrier tech - Fierce Biotech","headline":"Novartis inks $175M option deal for Sironax’s blood-brain barrier tech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1HanBvS2JpRFYyOF9MSG5mNjdJVnloMVJCNWlxb3ZtczBrM1VrOENpRHdQZy1aWDJMeHM2X0tNWEpQbG9qZVlrYjkzaFRGYkdTa1lZbklabENnSVVaZ1NZ?oc=5","date":"2025-05-07","type":"trial","source":"Nature","summary":"Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019 - Nature","headline":"Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQSFpjaGdWTm5BNEhKWHQtOWVZYzdhZFpFQVQta1ljdWhXcnNGTmN1MjRkMWlYMFlHSENJZUNsMmFIZ0Z4TnlFV3Q3emk3OUhVbzhEVXpfZWhSMTZMRWV4VW1jLWRFVnNGdHZOVVcyYkpEYzFQa092Mm50dHRmNnVKVGVrTUpkZVNETHow?oc=5","date":"2025-04-18","type":"pipeline","source":"washingtonpost.com","summary":"China’s restrictions on rare earths could hurt U.S. health care - washingtonpost.com","headline":"China’s restrictions on rare earths could hurt U.S. health care","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQc3ZxcXZRbWlUODZKZUVxWFB6VzZHQWJla0VHaVk2MGZES2p0ZDFTX21uT0s5SFJoNnpZVzMwRXhKTUFVcDhqMDE2MVhtblR0Uk14bHB6QXlXUHRPNFRRRGVRc2ZuMVVqUURKSmMxYkhLeWZJVUxhWTFLMzc2ZFdLVTBOMWl3UEtUQWV4SHdzM3dfYl9ITmhvX1dDcmJHMUVPZ1VqTzFHa0lBWDVIRmV0M3otZw?oc=5","date":"2025-03-26","type":"pipeline","source":"IQVIA","summary":"Global Trends in R&D 2025 - IQVIA","headline":"Global Trends in R&D 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE9jdExIRV9Lc1JKWEc1UXdrTEZsTTNYbjhjb3VJV05ONTUxck5tVUVRSTVsWWlhQVAzYVcxaDluZi10T1V3YnVrbk93X3ZrQWtVVTVWNURuOHRfbkEzQkk2N2tGY1Y?oc=5","date":"2025-01-08","type":"pipeline","source":"Boston Consulting Group","summary":"Biopharma Trends 2025 - Boston Consulting Group","headline":"Biopharma Trends 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQWS1SWGhZSlpkUndMVHJmZnA5clBub053NHpKR0YzRnQ3SGo5MmZ6RTNpWHc4VU5HYkNaQXpIeXl1RUFZREZBRktRVFZ4eF9GWWNhY1lWWjE0Q0pyU0JYRkE0TXM2VEtoeTZPT0h0VmdYQk9Zd2R6dlE4STdJYlF0SXVwZUFBU3AtZnc?oc=5","date":"2024-07-30","type":"pipeline","source":"Information Technology and Innovation Foundation (ITIF)","summary":"How Innovative Is China in Biotechnology? | Reports & Briefings | Jul 30, 2024 - Information Technology and Innovation Foundation (ITIF)","headline":"How Innovative Is China in Biotechnology? | Reports & Briefings | Jul 30, 2024 - Information Technology and Innovation F","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQcmlBeFFNMVpfbHpvdWg0VW5yTVgzU0g5UDAtancwaXpxVHVLcVppN0dTYlJDRUl4YWFvbExOYzd1eGZQOWpSbUlKOEdVR1FSNnllWEl0OTZYS1hiVjZrZVNhTzlFblQzQ3BiaU04TmNNWFRMcFVZazAyYW9HcjBfa3h2QzAxWFNKUllPc2UxajNWMnVyb2FaQzZn?oc=5","date":"2024-06-27","type":"pipeline","source":"Frontiers","summary":"Publication Trends for Alzheimer's Disease Worldwide and in China: A 30-Year Bibliometric Analysis - Frontiers","headline":"Publication Trends for Alzheimer's Disease Worldwide and in China: A 30-Year Bibliometric Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQV0w4NzNRZWYxWHF0Z21zTmZCbkM5cXNHdDNEaGQ2ek9nN0REcnktdHR6M3NiWUhZM3RNT3B6blBOdVVDSUFkZDNkazJ5enNsNThqdUFVM3ZJNlBpMDhJU2lKUVYzLWZmampCTVBGaGJNblgxb3NzQ3RjZ25odzRIQ08xdVEzS2NT?oc=5","date":"2021-10-14","type":"pipeline","source":"Science | AAAS","summary":"Exodus to Asia: Research opportunities abound - Science | AAAS","headline":"Exodus to Asia: Research opportunities abound - Science | AAAS","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":5},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}